Athira Pharma
Seattle
Athira Pharma develops novel small molecule therapies for diseases with limited treatment options, including metastatic breast cancer and ALS. Its lead drug candidates are lasofoxifene and brelgometon (ATH-1105), which are evaluated in clinical trials to improve care for patients through innovative research and product development.
Facts
- HQ
- Seattle
- Sectors
- Biotechnology, Pharmaceuticals
- Employees
- 49
Is this your organization? Claim it
Executives
-
Rachel Lenington Executive, Chief Operating Officer and Chief Development Officer
